Targeted therapies, such as anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies, have shown promise in patients with KRAS/NRAS wild-type tumors and microsatellite instability-high (MSI-H) cancers. This evidence concerns the gene EGFR and cancer.